Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy.

Brain Pathology
Johannes BergerSonja Forss-Petter

Abstract

Mutations in the ABCD1 gene cause the clinical spectrum of the neurometabolic disorder X-linked adrenoleukodystrophy/adrenomyeloneuropathy (X-ALD/AMN). Currently, the most efficient therapeutic opportunity for patients with the cerebral form of X-ALD is hematopoietic stem cell transplantation and possibly gene therapy of autologous hematopoietic stem cells. Both treatments, however, are only accessible to a subset of X-ALD patients, mainly because of the lack of markers that can predict the onset of cerebral demyelination. Moreover, for female or male X-ALD patients with AMN, currently only unsatisfying therapeutic opportunities are available. Thus, this review focuses on current and urgently needed future pharmacological therapies. The treatment of adrenal and gonadal insufficiency is well established, whereas applications of immunomodulatory and immunosuppressive drugs have failed to prevent progression of cerebral neuroinflammation. The use of Lorenzo's oil and the inefficacy of lovastatin to normalize very-long-chain fatty acids in clinical trials as well as currently experimental and therefore possible future therapeutic strategies are reviewed. The latter include pharmacological gene therapy mediated by targeted upregulat...Continue Reading

References

Sep 1, 1975·Archives of Neurology·H H SchaumburgE P Richardson
Jan 1, 1992·Journal of Inherited Metabolic Disease·H W MoserW Krivit
Nov 1, 1989·Neurology·W B RizzoJ A Sgro
Mar 1, 1982·Archives of Neurology·P O OstermanL O Nordesjö
Jan 1, 1981·Archives of Neurology·D A StumpfH H Schaumburg
Nov 1, 1994·Journal of Neurology, Neurosurgery, and Psychiatry·M CappaS Salvati
Mar 1, 1997·Journal of Inherited Metabolic Disease·G C KorenkeF Hanefeld
Nov 5, 1997·Biochemical and Biophysical Research Communications·A HolzingerA A Roscher
Jan 7, 1998·Journal of Neuroscience Research·S Forss-PetterK A Nave
Sep 5, 1998·The New England Journal of Medicine·I SinghS Pai
May 5, 1999·Neurochemical Research·K D SmithP A Watkins
Nov 7, 1999·The Journal of Biological Chemistry·L X LiuP Aubourg
Jan 19, 2000·Proceedings of the National Academy of Sciences of the United States of America·J KluckenG Schmitz
Apr 5, 2000·Journal of Neuropathology and Experimental Neurology·J M PowersH W Moser
Apr 13, 2000·Annals of Neurology·A VerripsJ A Smeitink
May 3, 2000·Lancet·B Halliwell
Dec 9, 2000·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·R BambauerR Latza
Jan 4, 2001·Journal of Neuropathology and Experimental Neurology·A G GilgI Singh
Oct 11, 2001·Molecular Genetics and Metabolism·M C McGuinnessK D Smith
Oct 11, 2002·Human Molecular Genetics·Isabelle WeinhoferJohannes Berger
Nov 14, 2002·The Biochemical Journal·Annemieke J M de RuijterAndré B P van Kuilenburg
Jan 2, 2003·Molecular and Cellular Biology·M C McGuinnessK D Smith
May 17, 2003·Nature Reviews. Drug Discovery·Tejvir S Khurana, Kay E Davies

❮ Previous
Next ❯

Citations

Aug 7, 2013·Thyroid : Official Journal of the American Thyroid Association·Sunitha MeruvuPaul Webb
Sep 27, 2012·BMC Neurology·Aia Elise JønchJørgen Erik Nielsen
Apr 10, 2015·British Journal of Haematology·Daniel Sanghoon ShinMichael H Rosove
May 25, 2012·Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición·Alma Prieto TenreiroAlberto Díez Hernández
Dec 21, 2011·Biochimica Et Biophysica Acta·Lucia CiccoliJoussef Hayek
Dec 22, 2015·Biochimica Et Biophysica Acta·Johannes BergerMarkus Kunze
Sep 18, 2015·Brain : a Journal of Neurology·Patricia L MusolinoFlorian S Eichler
Apr 15, 2011·British Journal of Pharmacology·Stephan KempRonald J A Wanders
Aug 26, 2015·Biochimica Et Biophysica Acta·Rebecca L FarrMarc Fransen
Jul 19, 2013·Case Reports in Neurological Medicine·Gyda Hlin Skuladottir JackMarianne Andersen
Mar 31, 2015·Cell Death and Differentiation·L MoratóA Pujol
Jun 1, 2016·Endocrinology and Metabolism Clinics of North America·Elizabeth Burtman, Molly O Regelmann
Apr 10, 2012·Biochimica Et Biophysica Acta·Stephan KempPatrick Aubourg
Jul 15, 2015·Cellular and Molecular Neurobiology·Marion DeonCarmen Vargas
Sep 10, 2013·Biochimie·Ronald J A Wanders
Dec 10, 2013·Biochimie·J BergerF S Eichler
Jan 1, 2015·Acta Neuropathologica·Nathalie LaunayAurora Pujol
Mar 15, 2012·Clinical Epigenetics·Roberto Berni CananiLudovica Leone
Feb 3, 2016·British Journal of Clinical Pharmacology·Mariam A AhmedGerald V Raymond
Feb 23, 2011·Arquivos brasileiros de endocrinologia e metabologia·Fernanda Caroline SoardiMaricilda Palandi de Mello
May 10, 2018·Disease Models & Mechanisms·Hannah B GordonAnthea Letsou
Apr 23, 2014·Biomolecules & Therapeutics·Takayuki Sassa, Akio Kihara
Dec 4, 2019·Current Opinion in Endocrinology, Diabetes, and Obesity·Liane Eng, Molly O Regelmann
Apr 6, 2018·Neurology. Clinical Practice·Takeo SatoHisayoshi Oka
May 3, 2020·Annals of Clinical and Translational Neurology·Bettina ZierfussJohannes Berger
Jul 16, 2010·Brain Pathology·Inderjit Singh, Aurora Pujol
May 12, 2019·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Carlos CasasnovasAurora Pujol
Feb 13, 2018·Antioxidants & Redox Signaling·Marc Fransen, Celien Lismont
Jul 16, 2010·Brain Pathology·Isidro FerrerAurora Pujol
Mar 15, 2020·Cell Chemical Biology·Meredith D HartleyThomas S Scanlan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Adrenoleukodystrophy

Adrenoleukodystrophy (ALD), the most frequent peroxisomal disorder, is an X-linked disorder caused by a defect in the metabolism of long chain fatty acids leading to demyelination, neurodegeneration, and death. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.